Effect of liver fibrosis on long-term mortality in HIV/hepatitis c virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1235-1243

  Sanmartin, Ramon ^a   De Felipe, Elena ^a   Tor, Jordi ^a   Sanvicens, Arantza ^a   Barluenga, Eva ^a   Martinez, Elisenda ^a   Muga, Robert ^a   Jou, Antoni ^a   Ojanguren, Isabel ^a   López, Juan José ^a   Clotet, Bonaventura ^a   Tural, Cristina ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURVIVAL; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DISEASE PROGRESSION; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL ANALYSIS;

EID: 84866680832     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0322     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al.: Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA study. AIDS 2002;16:1663-1671.
3. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006,166(15):1632-1641.
4. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al.: Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol 2009;50:736-745.
5. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713.
6. Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al.: Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006;20:49-57.
7. Berenguer J, Alvarez-Pellicer J, Martinez PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al.: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coin-fected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413.
8. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al.: Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009;49:1274-1282.
9. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al.: Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J He-patol 2008;48:200-207.
10. Poynard T, Bedossa P, and Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
11. Scheuer PJ: Classification of chronic hepatitis: A need for reassessment. J Hepatol 1991;13:372-374.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, and Bacon BR: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gas-troenterol 1999;94:2467-2474.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
14. Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, et al.: Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011;54:879-886.
15. El-Kamary SS, Jhaveri R, and Shardell MD: All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011;53:150-157.
16. Younossi ZM and Stepanova M: Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol 2010;8:718-723.
17. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, et al.: Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study. J Hepatol 2010;53:36-42.
18. Wise M, Bialek S, Finelli L, Bell BP, and Sorvillo F: Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008;47:1128-1135.
19. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, et al.: Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630.
20. Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, et al.: Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis 2009; 48:1467-1470.
21. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al.: Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-48.
22. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al.: Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011;52:1458-1465.
23. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al.: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-762.
24. Simard EP, Pfeiffer RM, and Engels EA: Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011;117: 1089-1096.
25. Zucchetto A, Suligoi B, De Paoli A, Pennazza S, Polesel J, Bruzzone S, et al.: Excess mortality for non-AIDS-defining cancers among people with AIDS. Clin Infect Dis 2010;51: 1099-1101.
26. Simard EP, Pfeiffer RM, and Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010;170:1337-1345.
27. Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, et al.: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010;116:5306-5315.
28. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
29. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-and Orengo JF: Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55.